{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:57:05Z","timestamp":1790211425030,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Arrhythmogenic right ventricular cardiomyopathy (ARVC) patients develop ventricular arrhythmias (VAs) responsive to anti-tachycardia pacing (ATP). However, VA episodes have not been characterized in accordance with the device therapy, and with the emergence of the subcutaneous implantable cardioverter defibrillator (S-ICD), the appropriate device prescription in ARVC remains unclear. Study aim was to characterize VA events in ARVC patients during follow-up in accordance with device therapy and elicit if certain parameters are predictive of specific VA events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This was a retrospective single-centre study utilizing prospectively collated registry data of ARVC patients with ICDs. Forty-six patients were included [54.0 \u00b1 12.1 years old and 20 (43.5%) secondary prevention devices]. During a follow-up of 12.1 \u00b1 6.9 years, 31 (67.4%) patients had VA events [n = 2, 6.5% ventricular fibrillation (VF), n = 14], 45.2% VT falling in VF zone resulting in ICD shock(s), n = 10, 32.3% VT resulting in ATP, and n = 5, 16.1% patients had both VT resulting in ATP and ICD shock(s). Lead failure rates were high (11\/46, 23.9%). ATP was successful in 34.5% of patients. Severely impaired right ventricular (RV) function was an independent predictor of VT resulting in ATP (hazard ratio 16.80, 95% confidence interval 3.74\u201375.2; P &amp;lt; 0.001) with a high predictive accuracy (area under the curve 0.88, 95%CI 0.76\u20131.00; P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>VA event rates are high in ARVC patients with a majority having VT falling in the VF zone resulting in ICD shock(s). S-ICDs could be of benefit in most patients with ARVC with the absence of severely impaired RV function which has the potential to avoid consequences of the high burden of lead failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad073","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T21:39:32Z","timestamp":1684791572000},"source":"Crossref","is-referenced-by-count":13,"title":["Right ventricular function is a predictor for sustained ventricular tachycardia requiring anti-tachycardic pacing in arrhythmogenic ventricular cardiomyopathy: insight into transvenous vs. subcutaneous implantable cardioverter defibrillator insertion"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0081-5739","authenticated-orcid":false,"given":"Shohreh","family":"Honarbakhsh","sequence":"first","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"},{"name":"William Harvey Research Institute, Queen Mary\u2019s University of London , London, E1 , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8595-7212","authenticated-orcid":false,"given":"Alexander","family":"Protonotarios","sequence":"additional","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-5453","authenticated-orcid":false,"given":"Christopher","family":"Monkhouse","sequence":"additional","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross J","family":"Hunter","sequence":"additional","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3383-3984","authenticated-orcid":false,"given":"Perry M","family":"Elliott","sequence":"additional","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9055-9267","authenticated-orcid":false,"given":"Pier D","family":"Lambiase","sequence":"additional","affiliation":[{"name":"The Barts Heart Centre, St Bartholomew\u2019s Hospital, Barts Health NHS trust , West Smithfield, London WC1 8BE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"2023052423172069200_euad073-B1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1540-8167.2012.02412.x","article-title":"Arrhythmogenic right ventricular cardiomyopathy 2012: diagnostic challenges and treatment","volume":"23","author":"Marcus","year":"2012","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2023052423172069200_euad073-B2","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehz103","article-title":"A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy","volume":"40","author":"Cadrin-Tourigny","year":"2019","journal-title":"Eur Heart J"},{"key":"2023052423172069200_euad073-B3","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/europace\/euac014","article-title":"Incidence and predictors of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: a pooled analysis","volume":"24","author":"Agbaedeng","year":"2022","journal-title":"Europace"},{"key":"2023052423172069200_euad073-B4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMra1509267","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado","year":"2017","journal-title":"N Engl J Med"},{"key":"2023052423172069200_euad073-B5","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/01.CIR.0000145610.64014.E4","article-title":"Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results","volume":"110","author":"Wathen","year":"2004","journal-title":"Circulation"},{"key":"2023052423172069200_euad073-B6","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.663807","article-title":"Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of &gt;10 years","volume":"115","author":"Kleemann","year":"2007","journal-title":"Circulation"},{"key":"2023052423172069200_euad073-B7","doi-asserted-by":"crossref","first-page":"e007691","DOI":"10.1161\/JAHA.117.007691","article-title":"Risk factors and temporal trends of complications associated with transvenous implantable cardiac defibrillator leads","volume":"7","author":"Koneru","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023052423172069200_euad073-B8","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/eurheartj\/ehac180","article-title":"A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy","volume":"43","author":"Cadrin-Tourigny","year":"2022","journal-title":"Eur Heart J"},{"key":"2023052423172069200_euad073-B9","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1093\/eurheartj\/ehac289","article-title":"Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator","volume":"43","author":"Jorda","year":"2022","journal-title":"Eur Heart J"},{"key":"2023052423172069200_euad073-B10","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1161\/CIRCEP.113.000392","article-title":"Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia\/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications","volume":"6","author":"Schinkel","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2023052423172069200_euad073-B11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.0000121738.88273.43","article-title":"Implantable cardioverter\/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients","volume":"109","author":"Wichter","year":"2004","journal-title":"Circulation"},{"key":"2023052423172069200_euad073-B12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ejechocard\/jer138","article-title":"Right ventricular systolic function assessment: rank of echocardiographic methods vs. cardiac magnetic resonance imaging","volume":"12","author":"Pavlicek","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"2023052423172069200_euad073-B13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-018-1330-3","article-title":"Echocardiographic evaluation of the right heart","volume":"130","author":"Schneider","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"2023052423172069200_euad073-B14","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.hrthm.2019.02.034","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"17","author":"Stiles","year":"2020","journal-title":"Heart Rhythm"},{"key":"2023052423172069200_euad073-B15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jacc.2014.04.035","article-title":"Ventricular arrhythmias in the North American multidisciplinary study of ARVC: predictors, characteristics, and treatment","volume":"64","author":"Link","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023052423172069200_euad073-B16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/europace\/euaa367","article-title":"EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS)","volume":"23","author":"Burri","year":"2021","journal-title":"Europace"},{"key":"2023052423172069200_euad073-B17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/europace\/euab162","article-title":"Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy","volume":"24","author":"Bosman","year":"2022","journal-title":"Europace"},{"key":"2023052423172069200_euad073-B18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1083\/jcb.201507018","article-title":"Plakophilin-2 loss promotes TGF-beta1\/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes","volume":"212","author":"Dubash","year":"2016","journal-title":"J Cell Biol"},{"key":"2023052423172069200_euad073-B19","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/eurheartj\/ehr472","article-title":"Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study","volume":"33","author":"Gomes","year":"2012","journal-title":"Eur Heart J"},{"key":"2023052423172069200_euad073-B20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.hrthm.2014.04.025","article-title":"Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator","volume":"11","author":"Groh","year":"2014","journal-title":"Heart Rhythm"},{"key":"2023052423172069200_euad073-B21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.hrthm.2018.01.004","article-title":"Predictors of electrocardiographic screening failure for the subcutaneous implantable cardioverter-defibrillator in children: a prospective multicenter study","volume":"15","author":"Campbell","year":"2018","journal-title":"Heart Rhythm"},{"key":"2023052423172069200_euad073-B22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/jce.12343","article-title":"Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening","volume":"25","author":"Olde Nordkamp","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2023052423172069200_euad073-B23","doi-asserted-by":"crossref","first-page":"e008782","DOI":"10.1161\/JAHA.118.008782","article-title":"Subcutaneous implantable cardioverter-defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia: a transatlantic experience","volume":"7","author":"Orgeron","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2023052423172069200_euad073-B24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijcard.2019.01.041","article-title":"Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: results from an Italian multicenter registry","volume":"280","author":"Migliore","year":"2019","journal-title":"Int J Cardiol"},{"key":"2023052423172069200_euad073-B25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.jacep.2020.05.036","article-title":"1-year prospective evaluation of clinical outcomes and shocks: the subcutaneous ICD post approval study","volume":"6","author":"Burke","year":"2020","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad073\/50436119\/euad073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/5\/euad073\/50436119\/euad073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T01:23:08Z","timestamp":1684977788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad073\/7175317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad073","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5]]},"published":{"date-parts":[[2023,5]]},"article-number":"euad073"}}